Accro Bioscience raises $50M to advance ulcerative colitis treatment
What's the deal? Accro Bioscience has closed a $50 million Series C financing round led by OrbiMed, a healthcare-focused investment firm. The funds will advance Accro's clinical pipeline for immune-mediated diseases, with a focus on ulcerative colitis.
Why now? The immune-mediated disease space — which includes conditions like ulcerative colitis — remains a major area of unmet medical need. Biotech investors continue to back companies with promising clinical-stage programmes, and Accro's progress appears to have reached an inflection point that justified a significant capital raise.
What could go wrong? Clinical-stage biotechs face steep odds. Drug candidates can fail in late-stage trials, regulatory timelines can slip, and competition in the inflammatory disease market is fierce, with established players like AbbVie and Johnson & Johnson already holding significant market share.
The signal: OrbiMed's willingness to lead a $50M round signals continued investor confidence in novel approaches to immune-mediated diseases. Despite a choppy biotech funding environment, companies with differentiated clinical programmes are still able to attract meaningful capital. This deal fits a broader pattern of specialist healthcare VCs doubling down on therapeutic areas with large patient populations and room for better treatments.
Read more: prnewswire.com
